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Abstract
Background: Pancreatic cancer has a dire prognosis and is associated with a high mortality. Palliative patients
have special needs and often seek help in integrative oncological concepts (IO) that combine conventional and
complementary therapies. Nevertheless there are few recommendations regarding IO in current cancer guidelines. The
aims of this study were to report on implementation of IO in everyday palliative care and to analyze patient survival in
advanced pancreatic cancer.
Methods: This multicenter observational study investigates the implementation of IO and length of survival of patients
suffering from advanced pancreatic cancer (stage IV). We analyzed patient’s survival by employing multivariable
proportional hazard models using different parametric distribution functions and compared patients receiving
chemotherapy only, a combination of chemotherapy and Viscum album (VA) treatment, and VA treatment only.
Results: Records of 240 patients were analyzed. Complementary therapy showed high acceptance (93 %). Most
frequent therapy was VA treatment (74 %) that was often administered concomitantly to chemotherapy (64 %).
Both therapies had positive effects on patient survival as they had significant negative effects on the hazard in
our log-normal model. A second analysis showed that patients with combined chemotherapy and VA therapy
performed significantly better than patients receiving only chemotherapy (12.1 to 7.3 month). Patients receiving
only VA therapy showed longer survival than those receiving neither chemotherapy nor VA therapy (5.4 to 2.5 months).
Our data demonstrates that IO can be implemented in the everyday care of patients without disregarding conventional
treatment. Patients combining VA with chemotherapy showed longest survival.
Conclusions: Our data demonstrate the importance and potential of health services research showing that IO
treatment can be successfully implemented in the every-day care of patients suffering from advanced pancreatic
cancer. Patients combining VA with chemotherapy showed longest survival. To address patients’ needs adequately,
future cancer guidelines might increasingly include comments on complementary treatment options in addition to
conventional therapies. Further studies should investigate the effect of complementary treatments on survival and
quality of life in more detail.
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Highlights
We examined the implementation of integrative oncology
in everyday care for palliative pancreatic cancer patients.
We used parametric models to analyze the hazard on
patient survival.
Complementary therapies are chosen by a high number
of patients.
Chemotherapy and complementary therapy with VA
extracts were associated with lower hazards.
Background
Pancreatic cancer is associated with a high mortality rate
and thus remains a dire diagnosis for the patient. It is
the eighth most frequent cancer diagnosis in Germany
and is the fourth most common cause of death from
cancer [1]. The nonspecific symptoms often lead to a
delayed diagnosis of advanced cancer, resulting in a poor
5-year survival of six to nine percent [2]. Radical resec-
tion of the pancreas with adjuvant chemotherapy is the
only curable approach [3], but only about 20 % of cases
are resectable at diagnosis [4]. For palliative treatment
chemotherapy has proven to be superior to best sup-
portive care only [5]. Since the work of Burris et al. in
1997 [6], gemcitabine monotherapy has been the standard
first line treatment [3, 7]. The combination of gemcitabine
with the epidermal growth factor receptor inhibitor er-
lotinib; a chemotherapy of oxaliplatin, irinotecan, fluo-
rouracil, and leucovorin (FOLFIRINOX) for patients
with good performance status; and recently published
albumin-bound paclitaxel followed by gemcitabine are
alternative options that have shown promising results
[8–10] and have found their way into current guidelines
[3, 7, 11]. Nevertheless, with 6.24 months for gemcita-
bine/erlotinib and 11.1 months for FOLFIRINOX, the
median survival remains poor. The shock of a cancer
diagnosis and facing mortality usually results in a
search for social support from family, friends or faith
communities [12]. Patients have needs related to deal-
ing with symptoms associated with disease or therapy,
which strongly affect their well-being [12]. The major
need that conventional medicine primarily focuses on is
the need to cure, or at least to prolong survival [12].
Cancer guidelines mostly focus only on this outcome.
Patients with advanced cancers often seek fulfillment of
their other needs through complementary and alterna-
tive medicines (CAM) [13–15]. Patient’s expectations
and motivations for using CAM are often not to cure,
but to strengthen their immune system and to manage
pain or other treatment-related side-effects [16]. The
feeling of being active in their own treatment, with
an associated level of self-control, is an important
motivation for using CAM [12]. This seems to be of
increased importance to patients with lengthy disease
and treatment durations [17]. Additionally, sometimes
patients see CAM as a last resort, providing hope in a
situation of extreme distress [16, 17].
The Concerted Action for Complementary and Alter-
native Medicine Assessment in the Cancer field classifies
such therapies as i) herbal products, ii) dietary ap-
proaches, iii) mind-body interventions, iv) manipulative
and body-based practices or v) other CAM. The number
of CAM-users has increased in recent years and is esti-
mated to make up ~40 % of all cancer patients [18].
Simultaneous administration of CAM and conventional
therapies without the knowledge of the physician always
bears the risk of interference with the standard treat-
ment [14]. In the concept of integrative oncology (IO)
this is addressed and a comprehensive, patient centered
treatment approach is planned and administered by a
team of experts from different fields to avoid treatment
interactions and to achieve the best possible outcomes
[14]. IO attempts to combine the best of complementary
and conventional therapies and to address patients’
needs beyond the alleviation of symptoms [14]. Al-
though many patients evidently use CAM, it is almost
not present in German guidelines [19] and is not docu-
mented in German official cancer registries [20]. In the
following article we present data on patients with ad-
vanced pancreatic cancer documented by the Network
Oncology, a conjoint clinical register of hospitals, practi-
tioners and out-patient centers focusing on an IO
concept [20]. We report on the amount and types of
received complementary and conventional therapies and
analyze patient’s survival.
Methods
The Network Oncology (NO) has received a positive
vote from the ethical committee of the Medical Associ-
ation Berlin and has been described recently [20]. Using
the NO clinical database, all consenting patients treated
between August 2005 and November 2014 were thor-
oughly assessed and analyzed. Records of 459 patients
with pancreatic carcinoma (ICD10 C25.*) were reviewed
[20]. TNM stages or documented metastases were trans-
lated into UICC stages. Only palliative patients of stage
IV at initial diagnosis (earliest recorded stage within a
month of diagnosis) were included. Surgical interven-
tions were coded according to the German procedure
classification 2013 (OPS), the German modification of
the international classification of procedures in medicine
(ICPM) by the World Health Organization (WHO).
Systemic therapies such as chemotherapy, targeted ther-
apies or application of extracts of European mistletoe
(Viscum album, VA) in the context of an integrative
oncological setting were documented with start and end
dates. According to the summary of medicinal product
characteristics (SmPCs) VA is indicated in cancer ther-
apy. The rationale is to improve health related quality of
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life (HRQL) by reducing therapy related symptoms and
improving cancer related symptoms [21] with positive
effects on coping, fatigue, sleep, exhaustion, nausea,
vomiting and anxiety [22]. Non-pharmaceutical inter-
ventions (NPI) such as art therapies, nursing interven-
tions or psychological therapies were documented as
dummy variables. Some therapy types were grouped like
nursing interventions (embrocation, compress and oil
dispersion bath), movement therapies (physiotherapy,
eurythmy therapy, ergo therapy), creative therapies (art
therapy, music therapy, modeling and crafts therapy)
and massage or lymph drainage. Censored patient sur-
vival was calculated from diagnosis date until recorded
death or until last documented contact. Patients with no
death date and no last contact date were excluded from
the survival analyses. Kaplan Meier survival was calcu-
lated for all patients. To analyze how different factors in-
fluence the hazard on patient’s survival we employed
proportional hazard models using different parametric
distribution functions (log-normal, log-logistic, Weibull,
Gompertz and extreme values). Tested parametric haz-
ard models showed evident problems in dealing with
long-term survivors. Therefore we excluded extreme
values and censored our data to a maximum of 2 years
of survival (730.5 days). We included the factors age,
gender, chemotherapy and VA as variables as well as the
individual number of NPIs and chose the model with
the highest maximum likelihood.
To assess the effect of combined chemotherapy and
VA therapy, we classified the data based on whether or
not a patient received chemotherapy, and if they re-
ceived VA therapy or not. VA therapy was defined as
lasting more than 4 weeks, while the non-intensive
group had VA therapy for less than 1 week or not at all.
To avoid bias, patients that lived less than 4 weeks were
excluded from these analyses. All analyses were con-
ducted using R 3.1.2 [R Foundation for Statistical
Computing, Vienna, Austria. http://www.R-project.org/].
Time event analyses used the R-packages ‘eha: Event
History Analysis’ version 2.4-2 by Göran Broström and
‘survival: a Package for Survival Analysis in S’ version
2.37-7 by Terry M. Therneau.
Results
Two hundred and forty (53.7 %) patients showed ad-
vanced cancer of UICC stage IV at first diagnosis.
Median age was 68 (range 68–89 years). 124 patients
were female (51.7 %). There was no significant difference
in age between male and female patients. For nine patients
a second, independent carcinoma was documented in the
patient records. In seven cases this diagnosis occurred
more than 1 year before the diagnosis of pancreatic can-
cer. Four of these cases were breast cancer diagnoses
(ICD10 C50.*), the other localities that occurred only once
were lung (ICD10 C34.*), prostate gland (ICD10 C61.*),
and uterus (ICD10 C55.*). In two cases (ICD10 C34.* and
C50.*) secondary diagnosis occurred 1 month and 4
months after the pancreatic diagnosis, respectively.
Two hundred twenty-one patients (92.1 %) received
a complementary therapy within an IO setting. 177
(73.8 %) received VA and 202 (84.1 %) received at
least one NPI. Relative frequencies of patients receiv-
ing additional therapies are shown in Fig. 1. Amongst
patients who received a NPI, the median number of
different NPI therapies was five and did not differ
between genders (W = 5640.5, p = 0.1676). 71.7 % of
the patients had three or more NPI. Some therapy
forms like nursing interventions were preferred by
women compared to men (Fisher exact test pNursing =
0.006; Fig. 2). 89.2 % of the patients treated with VA re-
ceived preparations subcutaneously, 35.2 % intravenously
and 19.3 % by intratumoral application (Table 1).
One hundred fifty-four patients (64.1 %) received
chemotherapy with cytostatic drugs. 148 (96.1 %) of
these patients received gemcitabine either as monother-
apy or in combination with other drugs at some point.
Thirty-two patients received a targeted therapy, mostly
erlotinib in combination with gemcitabine (21 patients),
or gemcitabine and oxaliplatin (2 patients), gemcitabine
and tamoxifen (1 patient) or a monotherapy (11 pa-
tients) at some point during therapy. The monoclonal
antibodies catumaxomab as monotherapy and bevacizu-
mab in combination with gemcitabine were also used
(each one patient). Five patients received radiation ther-
apy. In two cases the radiated locality was the area of
the pancreas, in two cases these were metastases along
the thoracic vertebra and in one case it was the lumbar
vertebra. 124 patients (51.6 %) underwent a surgical or
endoscopic intervention (Table 2).
Two hundred thirty-two patients were included in the
right censored survival analyses and for 58.2 % of these
we had exact death dates. The median survival was
7.9 months (CI95% 6.6–10.5). For seven patients a
survival of more than 2 years after diagnosis was docu-
mented. Five of these cases were censored with un-
known outcome. Maximum survival was 7.5 years; five
patients lived for more than 2 years, one for more than
five and two for more than 7 years. The proportional
hazard model with the highest log-likelihood had a
log-normal baseline distribution (-888.78), followed by
log-logistic (-890.17), Weibull (-892.68), Gompertz
(-898.49) and extreme value (-899.40). Figure 3 shows
the model fit of the hazard in comparison to the Cox
regression and of the according survival function in
comparison to the Kaplan-Meier curve. The fit of the
hazard was good. The models with the highest likeli-
hood all had in common that they allowed the hazard
to first increase and then decrease, while the Weibull
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function only allows a monotonous incline. Nevertheless
the model overestimates the hazard slightly from 11
months on. Accordingly the survival function slightly
underestimates the real data. Model results showed that
being male and of older age were associated with an
increasing hazard, while chemotherapy, as well as VA,
were associated with a decreasing hazard (Table 3).
Analysis revealed a significant survival benefit for pa-
tients that received chemotherapy in combination with
more than 4 weeks of VA (Gr 4) compared to patients
having chemotherapy alone (Gr 2) (log rank test, χ2 = 6,
p = 0.014, Fig. 4). Furthermore, the group receiving only
VA (Gr 3) showed longer survival than the best support-
ive care group (Gr 1), that received no chemotherapy
and no or almost no VA (log rank test, χ2 = 7.6, p =
0.006, Fig. 4). Table 4 summarizes and compares patient
characteristics and NPI use by subgroup. Global tests
showed significant differences in age, gender, total applied
NPI and nursing interventions.
Discussion
The present health services research data demonstrate
the use and acceptance of IO for palliative pancreatic
cancer patients. Complementary therapies in IO are ad-
juncts to conventional cancer treatment, used primarily
for symptom control, to enhance physical and emotional
strength of patients during and after conventional care.
Thus, IO aims to better address patients’ needs by com-
bining the best of conventional medicine and CAM in a
comprehensive way [14]. Claiming that only therapies
used that were shown to be safe and effective, IO in-
tends to prevent patients from harm by uncontrolled
Fig. 2 Odds ratios for male and female patients receiving a certain
type of therapy. Asterisks denote statistical significance (p < 0.05)
Fig. 1 Relative frequencies of additional therapies in men and women. Dark grey bars denote female, light grey bars denote male patients
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self-medication [14]. However, a common criticism is
that many CAM methods are implemented in IO with-
out sufficient risk-benefit analyses according to scientific
standards [23]. Recent studies within the NO have ad-
dressed this issue and demonstrated safety profiles for
key therapies used in IO settings [24, 25]. Patients in-
cluded in this study tended to be younger compared to
the German average of pancreatic cancer patients (men
70 year, women 76 years) [1]. This is in line with many
studies reporting that younger age is often associated
with CAM use [26]. However, demographic factors seem
not to influence survival in pancreatic cancer patients in
Germany [27]. A high percentage of our patients used
CAM, especially NPI that intend to alleviate symptom
burden and side effects, activate patient’s resources and
improve patient’s quality of life by intensified care and
attention. The latter might play a major role in our pa-
tient population, as three of the five most frequent NPIs
were therapeutic nursing interventions. According to
our analysis nursing interventions were significantly
more preferred by women reflecting our previous results
[20]. The importance of increased attention that focuses
on patient’s needs has been demonstrated by Temel et
al. [28], who showed significant improvements in HRQL,
mood and survival in advanced lung cancer patients re-
ceiving an early palliative care in comparison to patients
receiving standard care. Based on the individual needs of
the patient, the early palliative care focused on an early
psycho-oncological support and end of life care plan-
ning, including anticipation, prevention, and treatment
of suffering. It was adapted from the National Consensus
Project for Quality Palliative Care. Surprisingly, our data
revealed that less than 30 % of patients chose psycho-
social support (offered at the time of diagnosis) despite
the vast burden associated with the diagnosis. This ra-
ther low rate may relate to heterogeneity in offer and ac-
ceptance of psychosocial support within the various
participating centers and to incomplete documentation
of complementary therapies in the early years of the
study period.
Movement therapies were also common in our popu-
lation and might contribute to patient improvement by
giving the patient a feeling of still being able to lead an
active life. Although positive emotional states are able to
boost patients’ immune systems and have other benefits,
it is likely that no amount of well-being can overcome
Table 1 Number of patients receiving VA therapy
Total Female Male
VA therapy in general 176 73.3 % 93 75.0 % 83 71.6 %
Subcutaneous total 157 89.2 % 82 88.2 % 75 90.4 %
Intravenous total 62 35.2 % 32 34.4 % 30 36.1 %
Intratumoral total 34 19.3 % 13 14.0 % 21 24.4 %
Other total 4 2.2 % 3 3.2 % 1 1.2 %
Subcutaneous only 93 52.8 % 55 59.1 % 38 45.8 %
Intravenous only 6 3.4 % 5 5.4 % 1 1.2 %
Intratumoral only 6 3.4 % 2 2.2 % 4 4.8 %
Subcutaneous/intravenous 38 21.6 % 17 18.3 % 21 25.3 %
Subcutaneous/intratumoral 10 5.7 % 1 1.1 % 9 10.8 %
Intravenous/intratumoral 1 0.6 % 1 1.2 %
Subcutaneous/intravenous/intratumoral 15 8.5 % 8 8.6 % 7 8.4 %
The percentages in the first row refer to the total number of patients, other percentages refer to the number of patients receiving VA therapy
Table 2 Surgical and endoscopic interventions
Interventions Patients
Pancreatic interventions total 48 40
Inner drainage of the pancreas 1 1
Partial resection of the pancreas 19 19
Endoscopic intervention at the pancreatic duct 15 10
Anastomosis of the pancreatic duct 1 1
Other 12 12
Stomach interventions total 27 24
Intestine interventions total 29 23
Resections of small or large intestine 8 8
By-pass anastomosis of the intestine 5 5
Liver interventions total 15 15
Resections of the liver 14 14
Gall bladder or bile duct interventions total 105 49
Endoscopic interventions at the biliary tree 64 21
Other abdominal interventions total 43 35
Explorative Laparotomy 25 24
Other surgical or endoscopic interventions total 67 53
Port implantation 39 38
Splenectomy 4 4
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such serious diseases like pancreatic cancer [29].
Other frequently used mind-body interventions were
creative therapies that also address physical and emo-
tional needs. Evidence suggests that such interventions
might also have a positive impact on HRQL but more
research is needed to draw a conclusion on their
effectiveness [30, 31].
Generally, pancreatic cancer patients have a short
survival time with an overall 5-year survival rate of be-
tween six to nine percent in Germany [1, 2]. Review of
international literature and the SEER database, still
indicates a 5-year survival of less than five percent [4, 32,
33]. In our data restricted to palliative patients, we docu-
mented a 2-year survival for 3.3 % of the patients. Our
proportional hazard model demonstrated that older
people and males faced a slightly higher risk of dying,
whereas both chemotherapy and VA were associated with
a relevant decrease of the hazard.
For patients diagnosed with already advanced cancer
that received only best supportive care, a survival of 2.3
to 2.7 months is reported [33, 34], matching with our re-
sults of the stratified survival analysis. In our data this
patient population lived significantly shorter compared
to patients that received no chemotherapy but received
VA for at least 4 weeks. Anticancer therapy with VA ex-
tracts is common in German speaking countries [35]. It
has been reported to increase HRQL and attenuate ad-
verse drug reactions to conventional therapies [36–38].
Whether VA can contribute to survival is the issue of a
controversial debate [35]. A comprehensive overview on
the mode of action of VA extracts is given by the follow-
ing reviews [36, 39]. Results of our group on assessment
of safety of intravenous and subcutaneous VA therapy in
cancer patients revealed that it was safe with common
Fig. 3 The hazard and the survival predicted by the log-normal model in comparison to the Cox regression and the Kaplan-Meier curve
Table 3 Proportional hazard models on patient survival
Covariate w.mean Coefficient Exp (Coef) SE (Coef) Wald p
Intercept 1.613 1.730 0.351
Age 64.4 0.021 1.021 0.009 0.024
Male 0.5 0.423 1.540 0.179 0.016
Chemotherapy 0.8 -0.985 0.374 0.196 <0.001
VA therapy 0.9 -0.921 0.398 0.204 <0.001
Number of NPI 4.4 -0.010 0.990 0.032 0.765
‘w.mean’ is the weighted (against exposure time) means of the covariate;
weighted relative frequencies of levels of factors
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dose-related expected effects and mild local (<5 cm) or
temperature-related (<38 °C) adverse drug reactions and
no serious adverse reactions [24, 25]. From our data we
cannot conclude on the causality of VA and survival
prolongation, but our result matches the result of Tröger
et al. [40] in direction and magnitude. In their prospect-
ive randomized controlled study on VA treatment in
patients with advanced pancreatic cancer they found a
median survival of 4.8 months compared to 2.7 months
in the best supportive care group. Our data also shows
that VA alone seems not to be an equivalent to chemo-
therapy; but it might be a beneficial add-on to conven-
tional chemotherapy as these patients showed longest
survival. To evaluate the impact of VA as an add-on to
standard chemotherapy on survival further confirmative
randomized controlled trials are highly warranted. VA
is well tolerated with gemcitabine [41] and recent stud-
ies have indicated a possible influence of VA on survival
in patients with pancreatic carcinomas [42, 43]. This is
in line with a systematic literature review on VA and
cancer treatment [44]. A limitation of our study is that
survival is likely to be underestimated. Whenever there
was no exact death date documented we used the last
documented date related to the patient as last contact
date to calculate survival. The amount of censored data
to the number of documented deaths is almost constant
throughout the observed period. Nevertheless, missing
death dates affect the calculation of survival. Addition-
ally, as an observational study it suffers from potential
missing or erroneous data and a heterogeneous patient
Fig. 4 Kaplan Meier survival based on the UICC IV patients. Stratified for patients receiving no or less than 1 week of VA therapy and those who
had it for more than 4 weeks, as well as for patients receiving chemotherapy or not
Table 4 Patients characteristics of the subgroups Gr1 – Gr4
N Gender Age Number of NPI NPI
Male Female Min Max Median Min Max Median Total Creative
therapies
Movement
therapies
Nursing
therapies
Massages & lymph
drainage
Gr 1 24 41 % 59 % 39 85 74 0 9 3 79 % 29 % 54 % 46 % 42 %
Gr 2 40 35 % 65 % 39 77 65 0 8 4 85 % 60 % 55 % 66 % 48 %
Gr 3 43 16 % 84 % 39 89 73 0 10 5 93 % 65 % 74 % 86 % 53 %
Gr 4 107 57 % 43 % 39 84 66 0 12 4 88 % 60 % 78 % 77 % 61 %
X2 test Kruskal Wallis test Kruskal Wallis test X2 test X2 test X2 test X2 test X2 test
X2 = 29.56 X2 = 18.72 X2 = 9.93 X2 = 68.68 X2 = 1.24 X2 = 8.33 X2 = 14.14 X2 = 4.09
p < 0.001 p = 0.0003 p = 0.0191 p < 0.0001 p = 0.7426 p = 0.0396 p = 0.0027 p = 0.2523
Gr1 patients received no chemotherapy and no or less than 1 week of VA therapy. Gr2 patients got chemotherapy but no or less than 1 week of VA therapy. Gr3
patients received no chemotherapy but a minimum of 4weeks VA therapy. Gr4 patients received a combination of chemotherapy and minimum 4 weeks of VA
therapy. Non-parametric tests on group differences were made with a Bonferroni corrected α = 0.00625. Significant values p < 0.01 are shown in bold
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population. Another limitation of this study it that the
impact of the NPI in combination with conventional
and/or VA treatment cannot be assessed within our
data, since we are lacking systematic HRQL data. NPI
are not well described in terms of prognostic relevance.
However, there are positive effects of exercise on
cancer-related fatigue [45] and overall survival in pa-
tients with breast-, and colon cancer [46, 47] and cogni-
tive behavioral treatments and mindfulness orientated
therapies in cancer-related fatigue. Whereas multimodal
concepts are already established in chronic pain treatment
[48, 49], their evaluation in cancer therapy is relatively
new. In an exploratory analysis in breast cancer survivors
with chronic cancer-related fatigue, psycho- and sleep
education and eurythmy therapy where superior to aer-
obic training [50]. Patient-reported outcome measures
(PROMS) have been developed for many years [51] and
have been successfully applied in oncology [52–54].
While palliative chemotherapy in patients with end-
stage cancer has been questioned to improve quality of
life [55], in the future HRQL data and PROMS might
contribute to the evaluation of the influence of single
NPI-interventions and multimodal therapeutic approaches
in cancer treatment.
Despite these limitations, our study provides an accurate
picture of the current clinical use and the potential im-
portance of IO in caring for pancreatic cancer patients.
Conclusion
Our data demonstrates the importance and potential of
health services research showing that IO treatment can be
implemented in the every-day care of patients suffering
from advanced pancreatic cancer. It also shows that IO
treatment does not disregard conventional treatment. Our
results suggest that IO therapies might have a beneficial
effect on patient’s survival. However, there are few recom-
mendations regarding IO in the current cancer guidelines
[19]. As patients often use CAM, even without discussion
with their practitioner [56], more attention should be
given to this issue to help practitioners to address patients’
needs adequately and to prevent patients from harm by
unqualified self-medication. These data demonstrate how
health services research can reflect real life conditions and
thus might contribute to ongoing discussion of treatment
guidelines and direction of future research in this field.
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